Wedge Industrial (000534) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
9 Jul, 2026Executive summary
An independent audit was conducted on the 2024 financial statements, including related party transactions and fund movements, with a standard unqualified opinion issued on March 5, 2025.
The report specifically addresses non-operating fund occupation and other related party fund transactions as of December 31, 2024.
Significant events and developments
No inconsistencies were found between the summary table of related party fund movements and the audited financial statements.
The summary table should be read together with the audited financial statements for a complete understanding.
Segment performance
Major related party transactions include receivables and fund movements with subsidiaries and entities controlled by major shareholders.
Both operating and non-operating fund movements are detailed, with significant balances involving subsidiaries in the biomedical and precision casting sectors.
Latest events from Wedge Industrial
- Net profit rose 12.49% YoY on higher revenue and robust pharmaceutical segment growth.000534
Q2 20249 Jul 2026 - Q3 2024 saw double-digit profit growth, robust cash flow, and major investments in expansion.000534
Q3 20249 Jul 2026 - Revenue and profit surged, with robust growth in pharma and alloy businesses and strategic investments.000534
Q2 20259 Jul 2026 - Revenue and net profit rose over 10% year-over-year, with robust growth in high-temperature alloys.000534
Q1 20259 Jul 2026 - Revenue and profit surged over 20% year-over-year, led by high-temperature alloy sales.000534
Q3 20259 Jul 2026 - Revenue up 19.62% to ¥1.29B, net profit up 2.22%, with strong R&D and no cash dividend.000534
Q4 20259 Jul 2026 - Q1 2026 saw revenue and profit growth, negative cash flow, and major strategic investment in a subsidiary.000534
Q1 20269 Jul 2026